Source: Resumos. Conference titles: International Symposium on Pathophysiology and Toxicology/ISPAT. Unidade: FCF
Subjects: MELANOMA, IMUNOTERAPIA
ABNT
OLIVEIRA, Erica Aparecida de et al. TOP1 as a molecular signature in melanoma progression and resistance to BRAF and MEK inhibitors. 2018, Anais.. São Paulo: FCF/USP, 2018. Disponível em: http://simpac.wixsite.com/simpac/symposium-publications. Acesso em: 29 set. 2024.APA
Oliveira, E. A. de, Fernandes, D. K. A., Watanabe, L. R. M., Consolaro, M. E. L., & Maria-Engler, S. S. (2018). TOP1 as a molecular signature in melanoma progression and resistance to BRAF and MEK inhibitors. In Resumos. São Paulo: FCF/USP. Recuperado de http://simpac.wixsite.com/simpac/symposium-publicationsNLM
Oliveira EA de, Fernandes DKA, Watanabe LRM, Consolaro MEL, Maria-Engler SS. TOP1 as a molecular signature in melanoma progression and resistance to BRAF and MEK inhibitors [Internet]. Resumos. 2018 ;[citado 2024 set. 29 ] Available from: http://simpac.wixsite.com/simpac/symposium-publicationsVancouver
Oliveira EA de, Fernandes DKA, Watanabe LRM, Consolaro MEL, Maria-Engler SS. TOP1 as a molecular signature in melanoma progression and resistance to BRAF and MEK inhibitors [Internet]. Resumos. 2018 ;[citado 2024 set. 29 ] Available from: http://simpac.wixsite.com/simpac/symposium-publications